United States Antibody Drug Conjugates Industry Intelligence Could Skyrocket by 2032 - Full Analysis Inside

Antibody-Drug Conjugates (ADC) Market reached US$ 11.96 Billion in 2024 and is expected to reach US$ 30.42 Billion by 2033, growing at a CAGR of 11.2 % during the forecast period of 2025-2033.

DataM Intelligence has released an in-depth research report on "Antibody Drug Conjugates Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a 360° market perspective with detailed analysis on value, volume, and future development trends your ultimate guide to spotting high-impact opportunities and staying ahead in this dynamic market.

In 2024, global cancer cases reached around 20 million and are projected to exceed 35 million by 2050 a 77% surge driven by aging, population growth, and rising risk factors. This sharp increase, especially in low- and middle-income countries, is fueling demand for innovative treatments like ADCs to improve outcomes for both common and hard-to-treat cancers.

Download Your Sample PDF Today and (Get Priority Access With a Corporate Email ID For Faster Delivery):- https://datamintelligence.com/download-sample/antibody-drug-conjugates-market?kb

Mergers & Acquisitions

AbbVie continued its strong push in ADCs with the $10.1 billion acquisition of ImmunoGen, gaining access to marketed ADC Elahere and a deep investigational pipeline.

Johnson & Johnson acquired Ambrx Biopharma for $2 billion, securing synthetic biology technology for next-gen ADCs like ARX517 targeting prostate cancer.

Genmab bought ProfoundBio for $1.8 billion, obtaining rights to multiple ADC candidates and expanding clinical-stage oncology assets.

Merck & Co. agreed to pay $5.5 billion upfront for Daiichi Sankyo's ADC candidates, reflecting high pharma interest and investments in this modality

Key Dynamics

For example, Roche gained FDA approval for the first companion diagnostic in January 2025 to identify HER2-ultralow metastatic breast cancer patients eligible for Enhertu (trastuzumab deruxtecan) by Daiichi Sankyo and AstraZeneca, strengthening this segment in the global ADC market.

In June 2025, OBI Pharma partnered with US biotech TegMine Therapeutics under a Master Services Agreement focused on antibody-drug conjugates (ADCs). Additionally, in August 2024, GSK received FDA Breakthrough Therapy Designation for its B7-H3-targeted ADC, GSK5764227 (GSK'227), for relapsed or refractory extensive-stage small-cell lung cancer after platinum-based chemotherapy.

List of Top Key Players:

Pfizer, Inc., AstraZeneca, GSK plc, DAIICHI SANKYO COMPANY, LIMITED, F. Hoffmann-La Roche Ltd., Takeda Pharmaceutical Company Ltd., Gilead Sciences, Inc., ADC Therapeutics, Astellas Pharma Inc., ImmunoGen, Inc., ACROBiosystems, and RemeGen Co., Ltd., among others.

Key Developments

May 2025: Astellas Pharma licenses XNW27011 ADC from Evopoint Biosciences targeting CLDN18.2.

Feb 2025: Summit Therapeutics partners with Pfizer to test ivonescimab with Pfizer's ADCs in solid tumors.

Jan 2025: Boehringer Ingelheim licenses ADC technology from Synaffix B.V., a Lonza company.

Jan 2024: Johnson & Johnson acquires Ambrx Biopharma for ~$2B, expanding next-gen ADC portfolio.

Forecast Growth Projection:

Global Antibody Drug Conjugates Market Positioned for Strong Growth 2025-2032, Building on the steady momentum of 2024, the market is poised for remarkable expansion as leading players embrace innovative technologies and strategic advancements. This evolving landscape is unlocking lucrative opportunities for businesses to invest, scale, and stay ahead in an increasingly competitive and fast-moving market.

Market Research Process:

The Antibody Drug Conjugates Market research report by DataM Intelligence combines extensive Primary and Secondary research to provide powerful, in-depth insights. It examines key market drivers such as regulatory frameworks, evolving market conditions, competitive dynamics, historical trends, and breakthrough technologies, while spotlighting emerging innovations and potential challenges. This all-inclusive analysis uncovers high-growth opportunities and highlights possible barriers, equipping businesses to tackle market volatility and capture new avenues for success.

Buy Now & Get Instant Access to 360° Market Intelligence:- https://www.datamintelligence.com/buy-now-page?report=antibody-drug-conjugates-market

Market Segments:

The breast cancer segment is set to capture 39.3% of the global ADC market in 2024.

By Product Type: Adcetris, Perjeta, Kadcyla, Enhertu, Padcev, Trodelvy, Polivy, Others

By Target Type: CD30 Antibodies, HER2 Antibodies, CD22 Antibodies, Others

By Technology Type: Linker Technology, Payload Technology, Others

By Application: Breast Cancer, Blood Cancer, Skin Cancer, Lung Cancer, Others

By End-User: Hospitals, Cancer Centres, Others

FDA Approvals

In July 2025, the FDA granted Breakthrough Therapy designation to fam-trastuzumab deruxtecan-nxki (Enhertu) combined with pertuzumab as first-line treatment in HER2-positive breast cancer, based on impressive progression-free survival data.

FDA cleared Iksuda Therapeutics' investigational ADC IKS014 for advanced HER2-positive tumors, initiating Phase 1 trials showing early clinical promise.

Telisotuzumab vedotin (Emrelis) received accelerated approval in May 2025 for NSCLC patients with high c-Met protein expression, expanding ADC options in lung cancer.

Datopotamab deruxtecan (Datroway) was cleared for Trop-2-directed treatment in adult patients with metastatic NSCLC in early 2025, adding new targeted treatment option.

Global Growth Regions:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Opens the report with a comprehensive market overview, highlighting key segments by region, product type, and application. It presents a clear snapshot of market size, growth potential by segment, and both short- and long-term outlook.

Chapter 2: Showcases the most impactful insights, uncovering the emerging trends and disruptive forces shaping the industry's future.

Chapter 3: Delivers an in-depth competitive landscape analysis of the Antibody Drug Conjugates market, covering revenue shares, strategic moves, and the latest mergers & acquisitions.

Chapter 4: Features detailed profiles of leading players, including their revenue streams, profit margins, product portfolios, and key milestones.

Chapters 5 & 6: Present a granular breakdown of regional and country-level revenue performance, offering a precise view of market size, opportunities, and development prospects worldwide.

Chapter 7: Analyzes market segmentation by product type, revealing the growth potential of each category and spotlighting high-impact.

Chapter 8: Examines application-based market growth, identifying the fastest-expanding sectors and lucrative opportunities for expansion.

Chapter 9: Maps the entire industry supply chain, providing insights into upstream and downstream activities for a complete market perspective.

Chapter 10: Concludes with key findings and actionable takeaways, guiding stakeholders toward strategic decisions and future growth opportunities.

Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/antibody-drug-conjugates-market?kb

FAQ's

Q1: How fast is the Antibody Drug Conjugates Market growing?

A: The Market is experiencing strong growth and is projected to expand at a CAGR of 11.2 % from 2025 to 2032.

Q2: Which Region Leads Antibody Drug Conjugates Market growth?

A: North America is projected to hold 44.3% of the global ADC market in 2024, Asia-Pacific ADC market at 17.6%

Try DataM Subscription Services free for 2 days - Get Started@ https://www.datamintelligence.com/reports-subscription?kb

Make smarter moves with real-time competitor insights, strategic forecasts, and global investment trends-get it all now!

Access your Subscription Dashboard today@ https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.